A recent study shows that the presence of H. pylori bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c), an important biomarker for blood glucose levels and diabetes. This association was stronger in obese individuals with a higher Body Mass Index (BMI). The results, which suggest the bacteria may play a role in the development of diabetes in adults, are published in The Journal of Infectious Diseases and are now available online.
H. pylori infection of the stomach may be acquired in early childhood, become persistent, and can lead to gastric and duodenal ulcers; these bacteria have also been associated with an increased risk of gastric cancer. Treatment and eradication of these bacteria with antibiotics have cured many patients with ulcers, revolutionizing treatment of this disorder.
Type II diabetes causes an estimated 3.8 million adult deaths globally. There have been conflicting reports about the association between H. pylori infection and type II diabetes. To better understand the relationship between H. pylori and the disease, Yu Chen, PhD, and Martin Blaser, MD, at NYU School of Medicine, part of NYU Langone Medical Center, cross-analyzed data from participants in two National Health and Nutrition Surveys (NHANES III and NHANES 1999-2000) to assess the association between H. pylori and levels of HbA1c. According to the study authors, “H. pylori was consistently positively related to HbA1c level in adults, a valid and reliable biomarker for long-term blood glucose levels.”
In addition, this association was stronger in individuals with a high BMI compared to those with a lower value. The researchers hypothesized that H. pylori may affect the levels of two stomach hormones that help regulate blood glucose, and they suggest that eradicating H. pylori using antibiotics in some older obese individuals could be beneficial. More research will be needed to evaluate the health effects of H. pylori and its eradication among different age groups and in relation to obesity status, the authors noted.
An accompanying editorial points out that while previous studies have addressed the association between type II diabetes and H. pylori in small samples, this study analyzed two independent large national samples of the general population. The editorial authors agreed with the study investigators, suggesting that adults infected with H. pylori with higher BMI levels, even if asymptomatic, may need anti-H. pylori therapy to control or prevent type II diabetes. If the study findings are confirmed, lead editorial author Dani Cohen, PhD, of Tel Aviv University in Israel, noted, they “could have important clinical and public health implications.”
Published continuously since 1904, The Journal of Infectious Diseases is the premier global journal for original research on infectious diseases. The editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. The journal is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing more than 9,000 physicians and scientists who specialize in infectious diseases. For more information, visit www.idsociety.org.
Contact Name: Laurel White Contact E-mail: firstname.lastname@example.org Contact phone: 312-558-1770
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2016 Infectious Diseases Society of America